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Questionnaire (FHSQ)Abstract Background: Platelet-rich plasma (PRP) has been gaining popularity as a treatment for
plantar fasciitis (PF).
Aim of the work: To compare local autologous PRP and steroid injections both clinically and
sonographically within 3-months and also regarding its safety.
Patients and methods: This study was carried out on 50 patients with chronic PF divided into
two groups: steroid and PRP groups (n= 25 each). Patients were assessed by visual analog scale
(VAS), Foot Health Status Questionnaire (FHSQ) and ultrasonography at 1.5 and 3 months
post-injection.
Results: The 50 patients had comparable disease duration (p> 0.5). At 1.5 months post-injec-
tion, there was more improvement in the PRP than in the steroid group both clinically (as assessed
by the VAS) and ultrasonographically (as regards the echogenicity) (p= 0.008 and p< 0.01,
respectively). There was no significant difference between both groups at 3 months. The echogenic-
ity significantly improved at 3 months post-injection within each group (p< 0.0001). Regarding
thickness, the difference did not reach significance (p = 0.11, p> 0.05). No significant difference
was present between the 2 groups regarding the reduction plantar fascia thickness at 1.5
(p= 0.89) and 3 months (p= 0.64) post-injection. Regarding the safety of both injections, none
of our patients in either group developed any significant complications.gypt
248 N.A. Sherpy et al.Conclusions: We suggest that the PRP injection is a new, readily available, well tolerated and safe
choice of therapy for chronic PF and is not inferior to steroid injection in a short term 3 month fol-
low up. Comparing the long-term efficacy both clinically and sonographically is necessary to con-
firm their sustained effect.
 2015 The Authors. Publishing services provided by Elsevier B.V. on behalf of Egyptian Society of
Rheumatic Diseases. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Heel pain is a common presenting complaint in the foot and
ankle practice. Plantar fasciitis (PF) is the most common cause
of heel pain [1]. It tends to occur more often in women, middle-
aged, military recruits, athletes and the obese [2]. Approxi-
mately 10% of people suffer from PF at some point during
their lifetime [3].
Corticosteroid injections are used for cases of PF refractory
to conservative treatment and have been an effective modality
for pain relief [4]. However, the effect seems to be limited and
short-lived [5]. Also, a number of complications may occur of
which the most serious are plantar fascial rupture and plantar
fat pad atrophy. Fascial rupture interrupts the intrinsic
windlass mechanism of the foot and can promote further
inflammation in the surrounding tissue. In addition, plantar
fat pad atrophy diminishes subcalcaneal cushioning, availing
the plantar fascia to further insult and, hence, more pain [6].
Platelet-rich plasma (PRP) has been gaining popularity as a
treatment for PF. Injection of PRP is thought to be safe, and
not to interfere with the biomechanical function of the foot [7].
It is a component of whole blood that is centrifuged to a con-
centrated state, treated with an activating agent, and injected
into the affected area [8]. The basic biologic mechanism of
action of PRP is simple, after injection of PRP in an injured
area, it induces a local inflammation. The pro-inflammatory
mediators together with the growth factors released from the
granules of the platelets trigger the localized inflammation
and the wound healing cascade, resulting in the cellular
migration and proliferation, glycosaminoglycan and collagen
deposition, collagen maturation and remodeling of the healing
tissue at different stages of wound healing [9]. PRP therapy has
been shown to improve pain scores and functional ability and
to decrease plantar fascia thickness. In 2004, Barrett and
Erredge treated nine patients with chronic PF with
ultrasound-guided PRP injections. Seven patients reported
complete resolution of symptoms and showed sonographic
improvement [10]. Later on in 2011, Scioli performed PRP
injections for PF and noted marked reduction in pain, and
improved ability to stand and walk in nearly all his patients
[11]. Similarly, Ragab and Othman in 2012 evaluated 25
patients and reported that VAS significantly improved and
plantar fascia thickness dropped with PRP treatment [7].
There is still controversy regarding the effectiveness of PRP
injections compared with steroid injections in PF patients.
Omar et al. in 2012 carried out a randomized controlled trial
on 30 patients and found a significant improvement in pain
and foot function at 1.5 months after PRP compared to steroid
injection [12]. More recently, Shetty et al. in 2014 found a
better response with PRP injections at the end of a 3 month
follow up [13]. Moreover, Monto found sustained improve-
ment in the American Orthopedic Foot and Ankle Society(AOFAS) hind foot score at 3, 6, 12 and 24 months following
PRP injection [14].
To date, all previous studies in this field have either assessed
local autologous PRP injections alone clinically and
sonographically, or compared PRP with steroid injections only
clinically. The aim of this study was to compare local autolo-
gous PRP injections and local steroid injections both clinically
and sonographically within 3 months regarding its effect on
pain, function, thickness and echogenicity of the plantar fascia
and also regarding its safety.
2. Patients and methods
2.1. Patients
This study was carried out as a prospective, single-center,
randomized, blind comparative study on 50 patients with
chronic PF, attending the Rheumatology and Rehabilitation
outpatient clinic in Zagazig University Hospitals, Faculty of
Medicine. An approval had been obtained from the
Institutional Review Board (IRB) of Zagazig University and
all participants signed an informed consent.
Patients were included in the study if they were >18 years
old and had chronic PF (>3 months). Clinical diagnosis of the
patients was considered in those having inferior heel pain that
usually worsens with their first steps in the morning or after a
period of inactivity, with maximal tenderness over the antero-
medial aspect of the inferior heel. The diagnosis was also
confirmed by ultrasonography based on having plantar fascia
thickness greater than 4 mm.
Patients were excluded if they had bilateral PF (for
sonographic comparisons), received non-steroidal anti-
inflammatory drugs (NSAIDs) within 1 week before the study,
had a previous local injection or surgery for PF, had haemato-
logical disorder like anemia (hemoglobin < 7.0 g/dl), throm-
bocytopenia (platelets < 15,000/lL) or bleeding dyscrasias,
had associated inflammatory enthesitis such as spondy-
loarthropathies, cardiovascular, renal or hepatic disease,
bacteremia, cellulitis, skin ulceration, vascular insufficiency
or neuropathy related to heel, diabetes mellitus or allergy to
bupivicaine. Pregnant and breast feeding patients were also
excluded.
The chronic PF patients were allocated randomly using a
simple randomization method (odd for PRP and even for ster-
oid) into two equal groups (25 patients each) by one of the
researchers who injected the patients with either steroids or
PRP (not guided by ultrasound) and did not share in clinical
nor in ultrasonographic assessments: Group I (PRP) was
injected 3 ml PRP after local anesthetic injection [15] and
group II (steroid) was injected 2 ml triamcinolone acetonide
(40 mg/ml) with local anesthesia [16]. The clinical examiners
and sonographers were blind to the type of the given injection.
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Pre-injection all patients of our study were subjected to full
history taking, thorough physical examination, visual analog
scale (VAS: 0–100) [17], Foot Health Status Questionnaire
(FHSQ) which includes Short Form 36 (SF36) [18], complete
blood count (CBC) to exclude anemia and thrombocytopenia,
plain X-ray to detect calcaneal spur, and ultrasonography.
Patients were reassessed by VAS, FHSQ, and ultrasonography
at 1.5 and 3 months post-injection.
Sonographic examination was performed with 5–12 MHZ
linear array transducer (Medison R3) on both symptomatic
and asymptomatic heels. The patients lay prone and their
ankles dorsiflexed to 90. The thickness of the plantar fascia
was measured on the longitudinal view of the heel from the
anterior edge of the inferior calcaneal border. PF was defined
as plantar fascia thickness >4 mm or when there was >1 mm
difference in plantar fascia thickness between symptomatic and
asymptomatic heels in association of reduced echogenicity
and/or loss of definition of border of the fascia distal to the
antero-inferior border of the calcaneus [19].
Ultrasonographic examination was repeated in the same
visit by another sonographer to assess inter-readers’ reliability.
No significant difference was found between the two readers as
regards the plantar fascia thickness (t= 0.045, p= 0.9,
p> 0.05), and echogenicity (kappa agreement was 0.71
(good)) and was highly significant (p= 0.003, p< 0.01).
2.3. Preparation of PRP
It began with a venous puncture and subsequent collection of
specific volume of autologous blood from the patient (10-ml of
venous blood sample) [20] into a tube containing an anticoag-
ulant (sterile sodium citrated tubes). The tubes were
centrifuged at 1800 rotations/minute (rpm) (for 15 min)
separating plasma (top layer) from packed red blood cells
(RBCs) (bottom layer). The RBC layer is discarded and the
second centrifuge at 3500 rpm for 10 min yields a more concen-
trated platelet layer after extraction of platelet poor plasma.
Platelets rich in growth factors were obtained following
Anitua’s technique that recommends removal of leukocytes
because their presence has been associated with the release of
metalloproteases that could damage the tissues and prevent
tissue healing [21].Table 1 Comparison between the platelet-rich plasma (PRP) and st
(SF36) in chronic plantar fasciitis patients, pre-injection, at 1.5 and
Parameter PRP group (n= 25)
VAS, median (range)
Pre-injection 9 (8–10)
At 1.5 mo 1.5 (0–10)
At 3 mo 0 (0–10)*
SF 36, mean ± SD
Pre-injection 173.4 ± 16.2
At 1.5 mo 232.8 ± 64.1
At 3 mo 246 ± 66.7*
PRP: Platelet-rich plasma, VAS: visual analog scale, SF36: Short Form 3
* Significantly different from the corresponding value pre-injection (p<2.4. Injection technique
Patients lay in supine position. Skin of the heel was disinfected
by betadine. For the PRP group, after injecting 1-ml of local
anesthesia (mepivacaine) PRP was injected by the same syringe
in the tenderest area [15]. As soon as the needle was out, we
placed a bandage over the injected area. The patient was
observed for 10 min and then discharged. The same steps were
followed for the steroid group of patients except that 2 ml tri-
amcinolone acetonide (40 mg/ml) was injected with local anes-
thesia [16]. After the procedure, patients were not allowed to
bear weight for 3 days. They were advised to wear comfortable
shoes, and avoid running and other high impact activities for
10 days. A standard stretching program for plantar fascia
was given to all patients [15].
As PRP effectively induces an inflammatory response, some
patients experienced minimal to moderate discomfort follow-
ing the injection which may last for up to 1 week. They were
instructed to ice the injected area if needed for pain control
and modify activity as tolerated. We recommended acetamino-
phen as the optimal analgesic, and avoided use of NSAID’s
throughout our 3 month follow up period as they exhibit
anti-platelet and anti-coagulant effects, which may diminish
the effectiveness of PRP [22].
2.5. Statistical analysis
Data were analyzed by the Statistical Package for the Social
Sciences (SPSS) software version 20.0. Differences between
qualitative variables were compared by Chi-square test (v2)
and differences between quantitative variables in two groups
were compared by Student’s t test (parametric) and by
Mann–Whitney U test (non-parametric). Multiple quantitative
data were compared by ANOVA test (parametric) and by
Kruskal–Wallis test (non-parametric). Kappa agreement was
used to test agreement between findings of the two sonogra-
phers. Significance was considered at p-value <0.05.
3. Results
There was no significant difference between the two groups
regarding age (PRP group: 37.48 ± 8.75 years, steroid group:
38.52 ± 6.2 years) and sex (PRP group: F:M= 23:2, steroid
group: F:M = 25:0) (p> 0.05). Disease duration in the PRPeroid groups regarding visual analog scale (VAS) and short form
3 months post-injection.
Steroid group (n= 25) t p
10 (9–10) 1.7 0.07
4 (0–9) 2.6 0.008
1 (0–9)* 1.1 0.24
171.2 ± 11.5 0.55 0.58
225.2 ± 38.9 0.51 0.62
249 ± 73.22* 0.15 0.88
6.
0.001).
Figure 1 Comparison between the platelet-rich plasma (PRP)
and steroid injection groups of patients with chronic plantar
fasciitis as regards the Foot Health Status Questionnaire (FHSQ)
foot domains at 1.5 months post-injection (Upper bar chart)
(t= 3.51, 3.41, 3.45 and 4.05 for foot pain, function, wear and
health respectively; p< 0.001 each) and at 3 months post-
injection (t= 0.88, 1.11, 0.86 and 1.31 respectively; p> 0.05).
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7.58 ± 1.02 months and the difference was also insignificant
(p> 0.05). Calcaneal spur was found in only 4 patients of
the PRP group and in 14 of the steroid group. Table 1 shows
the VAS and SF36 in the two groups pre-injection, 1.5 months
and 3 months post-injection. At 1.5 months post-injection
there was a significant difference between both groups regard-
ing VAS (p< 0.01). The difference between pre-injection and
3 months post-injection FHSQ within each group was highly
significant (p< 0.001). Fig. 1 shows the FHSQ in both groups
at 1.5 and 3 months post-injection. There was a significant
improvement in the FHSQ at 1.5 months post-injection in
the PRP group compared to the steroids group (p< 0.001).Table 2 Comparison between the platelet-rich plasma (PRP) and ste
fasciitis patients, pre-injection, at 1.5 and 3 months post-injection.
Parameter PRP group (n = 25) St
Thickness
Pre-injection 6.18 ± 1.51 5.
At 1.5 mo 5.68 ± 1.65 5.
At 3 mo 5.19 ± 1.66 5.
Echogenicity
Pre-injection
Normoehoic 0 (0) 0
Hypoechoic 25 (100) 25
At 1.5 mo
Normoechoic 20 (83.3)* 9
Hypoechoic 4 (16.7) 16
At 3 mo
Normoechoic 20 (83.3) 19
Hypoechoic 4 (16.7) 5
PRP: Platelet-rich plasma.
* = Significantly different from the corresponding value pre-injectionTable 2 and Figs. 2 and 3 show the sonographic findings
(plantar fascia thickness and echogenicity) in the two groups
pre-injection, 1.5 and 3 months post-injection. The echogenic-
ity significantly improved at 3 months post-injection within
each group (p< 0.0001). Regarding thickness, the difference
did not reach significance (p= 0.11, p> 0.05). No significant
difference was present between the 2 groups regarding the
reduction plantar fascia thickness at 1.5 (p= 0.89) and
3 months (p= 0.64) post-injection. A significant improvement
in echogenicity was present at 1.5 months between the two
groups favoring the PRP group (p< 0.01). At 3 months
post-injection no significant difference was observed between
both groups as more patients from the steroid group became
normoechoic (p= 0.7). Regarding the safety of both injec-
tions, none of our patients in either group developed any sig-
nificant complications.
4. Discussion
Plantar fasciitis is the most common cause of heel pain [1] and
injury of the plantar fascia [23]. Our study was designed to
compare the effect of autologous PRP injection with the classic
steroid injection in treatment of chronic PF both clinically and
sonographically within 3 months, noticing its short-term effi-
cacy and safety.
Our results showed that both groups showed significant
clinical and sonographic improvement at the end of the
3 months follow up period without any complications. More
improvement, both clinical and sonographic, was observed in
the PRP than in the steroid group at 1.5 months post-
injection. The early improvement with PRP is most probably
mediated by the excessive amount of growth factors and
cytokines that creates an inflammatory response that subse-
quently restarts the cycle of tendon repair interrupting the
stagnant healing environment [24]. While with steroid injec-
tions it only serves as an anti-inflammatory agent that ceases
the inflammation early within days and has a negligible effect
on regeneration, remodeling and maturation phase [25] which
occurs at a much slower rate compared with the PRP environ-
ment rich in growth factors.roid groups regarding the sonographic findings in chronic plantar
eroid group (n = 25) t p
67 ± 0.73 0.62 0.54
45 ± 0.77 0.14 0.89
14 ± 0.65 0.47 0.64
v2 p
(0) 0 1
(100)
(36) 11.3 <0.01
(64)
(79.2)* 0.13 0.7
(20.8)
(p< 0.0001).
A B C
Figure 2 Sonographic changes in PRP group. A: (before injection) plantar fascia thickness was 6.58 mm and fascia is hypoechoic. B:
(after 45 days) thickness was 4.81 mm and echogenicity was better. C: (after 3 months) thickness was 3.77 mm and fascia became
hyperechoic.
A B C
Figure 3 Sonographic changes in steroid group. A: (before injection) plantar fascia thickness was 6.58 mm and fascia was hypoechoic. B:
(after 45 days) thickness was 5.54 mm and fascia was still hypoechoic. C: (after 3 months) thickness was 4.91 mm and fascia became
hyperechoic.
Comparison of local autologous PRP and steroid injections 251At the completion of the study at 3 months, neither the
PRP group nor the steroid group proved to have better
improvement regarding clinical parameters. Also sonographi-
cally, although the reduction in plantar fascia thickness
remained insignificant between the two groups throughout
the 3 months, the percentage of normoechoic patients in the
PRP group remained constant while more patients in the ster-
oid group became normoechoic making the difference between
them which was significant at 1.5 months insignificant at
3 months. This is probably due to the slower healing in the
steroid injection group which finally became comparable to
the PRP group at 3 months.
The results of our study showing a good response to PRP
injections at the end of 3 months follow up was supported
by several previous studies on PRP in chronic PF [7,10,11].It was also consistent with another study on PRP injection
in patients with chronic tendinopathy/fasciopathy in the upper
and lower limbs as 84% of patients had an improvement in
echo texture whereas the reduction in maximal thickness did
not reach statistical significance (p< 0.09) [26]. On the other
hand in 2013, the Cochrane database review on eight different
soft tissue injuries concluded that overall, there is still insuffi-
cient evidence to support the use of PRP for treating muscu-
loskeletal soft tissue injuries, but it considered the need for
future randomized controlled trials on specific clinical condi-
tions rather than multiple different conditions and the need
for standardization of PRP preparation methods [27].
Our PRP versus steroid comparison matched the results of
recent studies as that of Omar et al. who found a significant
difference as regards VAS and FHSQ between the two groups
252 N.A. Sherpy et al.favoring the PRP group at 1.5 months follow up (p< 0.05)
[12] and also that of Monto who demonstrated that both
PRP and steroid groups continued to improve up to 3 months
and found that the improvement in the steroid group started to
decline after 3 months and was sustained for longer periods in
the PRP group [13].
In the current study, only four patients had a calcaneal spur
on radiography in the PRP group showing no improvement
neither clinically nor radiologically while patients with spurs
in the steroid group showed improvement. The randomized
selection of patients is thus a limitation of this study. A longi-
tudinal larger scale study is required as further follow up
beyond three months could help in detecting which group will
show sustained clinical and sonographic improvement on a
long-term follow up.
To the best of our knowledge this is the first study to com-
pare PRP and steroid injections for chronic PF both clinically
and sonographically. It could be concluded that although the
cost of a PRP injection is higher than a steroid injection,
PRP injections can still be considered a readily available, well
tolerated and safe choice of therapy for chronic PF. The effi-
cacy of PRP injections in treating PF was found to be compa-
rable to steroid injections in short-term follow up with earlier
initiation of healing. Comparing the efficacy of PRP and ster-
oid injections both clinically and sonographically in long-term
follow up is necessary to see which will have a sustained effect
beyond 3 months since all previous studies were based on clin-
ical assessments only.
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